Peptide vaccine shows promise in head and neck cancer trial
NCT ID NCT04445064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a peptide-based immunotherapy in 17 people with head and neck cancer who were scheduled for surgery. The goal was to see if the vaccine could boost the immune system's attack on cancer cells and to check for side effects. The trial was stopped early, but the results help researchers understand how to better target this type of cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHARYNX SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aiming to spare the neck: could smarter radiation cut side effects in oral cancer?
- Less neck surgery may be just as effective for oral cancer with one affected node
- Bee product may boost health in oral cancer survivors
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
- New pastille could change head and neck cancer treatment
- New study aims to cut side effects in throat cancer treatment